Indication
Unresectable Locally Advanced Urothelial Cancer
1 clinical trial
4 products
Clinical trial
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
DurvalumabProduct
TremelimumabProduct
Cisplatin + GemcitabineProduct
Carboplatin + Gemcitabine